A detailed history of Israel Englander (Millennium Management LLC) transactions in Exagen Inc. stock. As of the latest transaction made, Millennium Management LLC holds 14,403 shares of XGN stock, worth $36,295. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,403
Previous 23,860 39.64%
Holding current value
$36,295
Previous $37,000 29.73%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.36 - $2.05 $12,861 - $19,386
-9,457 Reduced 39.64%
14,403 $26,000
Q1 2024

May 15, 2024

BUY
$1.42 - $2.3 $347 - $563
245 Added 1.04%
23,860 $37,000
Q4 2023

Feb 14, 2024

SELL
$1.45 - $2.39 $9,265 - $15,272
-6,390 Reduced 21.3%
23,615 $46,000
Q2 2023

Aug 14, 2023

SELL
$2.36 - $3.48 $7,434 - $10,962
-3,150 Reduced 9.5%
30,005 $87,000
Q1 2023

May 15, 2023

SELL
$2.23 - $2.9 $7,653 - $9,952
-3,432 Reduced 9.38%
33,155 $81,000
Q4 2022

Feb 14, 2023

SELL
$2.1 - $3.4 $27,134 - $43,931
-12,921 Reduced 26.1%
36,587 $88,000
Q3 2022

Nov 14, 2022

SELL
$2.69 - $8.68 $81,025 - $261,450
-30,121 Reduced 37.83%
49,508 $134,000
Q2 2022

Aug 15, 2022

BUY
$4.18 - $7.74 $332,849 - $616,328
79,629 New
79,629 $457,000
Q1 2022

May 16, 2022

SELL
$7.12 - $11.06 $208,573 - $323,991
-29,294 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$8.97 - $14.08 $50,743 - $79,650
-5,657 Reduced 16.19%
29,294 $341,000
Q3 2021

Nov 15, 2021

SELL
$10.25 - $15.21 $421,346 - $625,237
-41,107 Reduced 54.05%
34,951 $475,000
Q2 2021

Aug 16, 2021

BUY
$12.4 - $17.92 $943,119 - $1.36 Million
76,058 New
76,058 $1.14 Million
Q4 2019

Feb 14, 2020

SELL
$12.61 - $28.48 $478,726 - $1.08 Million
-37,964 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$14.5 - $17.5 $550,478 - $664,370
37,964 New
37,964 $588,000

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $41M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.